Curex Clinical Gaps and Limitations: What They Miss

What Curex actually offers in 2026

Curex is best known for allergy care, but it also operates a separate weight-management service. Its current GLP-1 program page advertises compounded semaglutide and tirzepatide in two forms: weekly injections and daily oral dissolving tablets. Curex says patients complete a medical intake, a clinician reviews the information, medication ships from a state-licensed pharmacy if prescribed, and patients receive ongoing follow-up, dose adjustment, and review of lab results.

The page advertises semaglutide starting at $149 and tirzepatide starting at $199, with the prescription, medication, and shipping included. These are advertised starting prices, not a guarantee of one fixed lifetime cost. Dose, formulation, availability, clinician approval, and changes to the program can affect what a person can actually order. The Curex weight-loss terms also make clear that access is subject to eligibility, location, and provider judgment.

That description corrects two errors in the former article. Curex is not simply a consultation subscription with medication always purchased separately, and its public site does claim ongoing support and lab-result review. A fair critique should evaluate the service Curex currently advertises, not an invented version of it.

The strongest questions concern the product and the clinical process behind the marketing: What exactly is compounded? Why is a compound medically appropriate for this patient? Which pharmacy dispenses it? What evidence supports the route and dose? Which baseline findings change eligibility? How often is response assessed? Curex's public landing page does not answer all of those questions.

Gap 1: compounded is not the same as FDA approved

The Curex page repeatedly labels its medications as compounded. That distinction is clinically important. The FDA's current page on unapproved GLP-1 drugs used for weight loss states that compounded versions do not undergo FDA review for safety, effectiveness, or quality before marketing. They are not FDA-approved generics and should not be represented as the same product as Wegovy or Zepbound.

Compounding is not automatically unlawful or inappropriate. Federal law allows patient-specific compounding under defined conditions when an approved product cannot meet an individual's medical need. But the broad shortage-based window changed. FDA determined that shortages of semaglutide and tirzepatide injection products were resolved, and the temporary enforcement periods tied to shortage status ended in 2025. The agency's GLP-1 compounding policy update says neither semaglutide nor tirzepatide is currently on the drug-shortage list or the 503B bulks list.

In February and March 2026, FDA announced stepped-up action against mass-marketing of non-approved GLP-1 copies and misleading claims of sameness. Its March 2026 telehealth announcement emphasized that compounded drugs are not FDA-approved and are not the same as approved generic drugs.

This does not establish that any individual Curex prescription violates the law. It does mean that the patient-specific basis, pharmacy category, formulation, and marketing claims matter. A service built primarily around compounds should make those details easy to verify before payment.

Gap 2: branded injection trials do not validate every compound

Semaglutide and tirzepatide have strong obesity evidence in their approved formulations. The STEP 1 trial randomized 1,961 adults without diabetes to once-weekly subcutaneous semaglutide 2.4 mg or placebo, both with lifestyle intervention. Mean weight change at 68 weeks was minus 14.9% with semaglutide and minus 2.4% with placebo.

The SURMOUNT-1 trial randomized 2,539 adults without diabetes to once-weekly subcutaneous tirzepatide or placebo. Mean weight changes at 72 weeks were minus 15.0%, 19.5%, and 20.9% at the 5, 10, and 15 mg maintenance doses, compared with minus 3.1% with placebo.

Those results establish efficacy for the studied products, doses, routes, manufacturing controls, and trial populations. They do not automatically establish bioequivalence, stability, purity, dose accuracy, or clinical outcomes for a compounded vial. They establish even less for a formulation that changes the route from subcutaneous injection to dissolution under the tongue.

FDA has reported dosing errors with compounded injectable semaglutide, including errors involving vial concentration, syringe units, prescribed amounts, and titration. The agency also warns that semaglutide sodium and semaglutide acetate are different active ingredients from the semaglutide base used in approved products, and says it is not aware of a lawful basis for using those salts in compounding. These are national concerns and are not evidence of a Curex-specific incident. They are reasons to verify the exact product on the prescription and pharmacy label.

Gap 3: the dissolving-tablet evidence is especially thin

Curex advertises compounded semaglutide and tirzepatide oral dissolving tablets that dissolve under the tongue. This is not simply a needle-free version of a weekly injection.

FDA-approved Wegovy labeling now includes a once-daily swallowed semaglutide tablet with a specific dose-escalation schedule. The approved tablet is taken on an empty stomach with a small amount of water, followed by a waiting period before food, drinks, or other oral medicines. Oral semaglutide uses the absorption enhancer SNAC and is absorbed through the stomach. A pharmacoscintigraphic study documented tablet erosion and gastric absorption characteristics for that formulation; see PMID 33750044.

A Curex tablet marketed to dissolve under the tongue is a different dosage form, route, and formulation. The approved Wegovy tablet therefore cannot be used as proof that a compounded sublingual tablet has the same exposure or weight-loss effect. Tirzepatide has an FDA-approved subcutaneous product, Zepbound, but no FDA-approved oral or sublingual tirzepatide product.

A 2026 analysis in Annals of Pharmacotherapy found that commercial compounded semaglutide and tirzepatide products used unique formulations, frequently sublingual or orally disintegrating, for which efficacy and safety were largely unknown. See PMID 41689811. A proof-of-concept sublingual semaglutide pharmacokinetic study published in 2026 was conducted in rats, not people. That is development-stage evidence, not validation of a marketed human weight-loss tablet.

Before choosing an ODT, ask for human pharmacokinetic data on the exact formulation, the actual milligram dose and excipients, how absorption variability is managed, and what outcome evidence supports the titration schedule. If the only efficacy numbers offered come from STEP 1, SURMOUNT-1, or approved oral Wegovy, the evidence does not match the Curex product being sold.

Gap 4: pharmacy and formulation details are not prominent

Curex says medications ship from a state-licensed pharmacy in its network. The main program page does not prominently identify the dispensing pharmacy, whether it operates under section 503A or 503B, the active ingredient manufacturer, whether semaglutide base or a salt is used, or the concentration and inactive ingredients for each advertised form.

Some information may appear after intake, on the prescription, or on the pharmacy label. It should still be available before a patient commits to a formulation. At minimum, verify:

• the legal name and state license of the dispensing pharmacy
• whether the product is an injection, swallowed tablet, or sublingual ODT
• the active ingredient and whether semaglutide is the base form rather than a salt
• concentration in milligrams per milliliter for a vial, not only syringe “units”
• the exact dose delivered by each tablet or measured injection
• storage temperature, beyond-use date, and what to do if a shipment arrives warm
• the patient-specific clinical reason an approved product does not meet the need
• whom to contact for a dosing or quality problem after delivery

FDA recommends filling GLP-1 prescriptions at a state-licensed pharmacy and contacting the compounder or telehealth platform with questions about instructions or labeling. It also advises against using an injectable product that arrives warm when refrigeration is required.

Gap 5: Curex says it reviews labs, but the protocol is not public

The Curex landing page says ongoing support includes adjustments, follow-ups, and review of lab results. That is meaningfully different from a service offering medication with no follow-up. The unresolved question is what Curex requires rather than what it can review.

The public page does not list a mandatory baseline panel, minimum clinician-visit cadence, escalation checkpoints, or thresholds that pause treatment. There is no single universal lab panel required for every GLP-1 patient, so the former article was wrong to attribute a fixed glucose, lipid, liver, kidney, and thyroid panel to Endocrine Society and AGA guidelines. Testing should follow the indication, medical history, current medicines, symptoms, and the product label.

The clinical intake should still resolve important issues. Current Wegovy and Zepbound labels require review of personal or family history of medullary thyroid carcinoma and MEN2, pregnancy, hypersensitivity, severe gastrointestinal disease, gallbladder and pancreatic history, kidney risk during dehydration, and concomitant medicines. Tirzepatide also has specific oral-contraceptive counseling during initiation and dose escalation. Diabetes medicines can require coordinated adjustment as intake and weight change.

Ask Curex which findings make a patient ineligible, whether a clinician verifies the medication list, when kidney or metabolic testing is ordered, how gastrointestinal symptoms alter escalation, and whether follow-up is scheduled or entirely patient initiated. “Unlimited support” describes availability. It does not by itself define a monitoring protocol.

Gap 6: weight management is more than fulfillment

The AGA obesity pharmacotherapy guideline recommends medication in addition to lifestyle intervention for qualifying adults whose response to lifestyle intervention alone is inadequate. Curex's public GLP-1 page emphasizes medication access, price, shipping, and support. It does not clearly promise registered-dietitian visits, a structured nutrition curriculum, resistance training, behavioral therapy, or coordinated management of sleep apnea, diabetes, cardiovascular disease, or eating disorders.

Not every patient needs every specialty service. But large weight changes affect protein intake, lean mass, blood pressure medicines, glucose-lowering therapy, gallbladder risk, fertility planning, and chronic-disease care. A telehealth prescriber should either manage those issues or make the handoff explicit.

The distinction also matters when quoting trial results. STEP 1 paired medication with repeated lifestyle counseling. SURMOUNT-1 included lifestyle intervention. Quoting their percentages beside a medication-only checkout experience can imply that the platform reproduces the trial, even when the surrounding support and exact product differ.

Gap 7: Curex-specific outcomes are not shown

The current program page displays consumer ratings and describes general GLP-1 benefits, but it does not present a Curex-specific clinical cohort with a defined denominator, formulation, dose, follow-up duration, attrition rate, mean weight change, or adverse-event rate.

That absence does not prove the program is ineffective. It limits what can be claimed about the delivery model. A review count cannot answer how many starters remain in care at 6 or 12 months, how injectable and ODT outcomes differ, how many stop for side effects, or how many transition to an approved product.

Long-term planning matters because obesity pharmacotherapy is generally chronic treatment. In the STEP 1 extension, participants regained about two-thirds of their prior weight loss during the year after semaglutide and lifestyle intervention were withdrawn. That finding came from a branded trial, but the care-planning lesson is broader: the initial monthly price is only one part of the decision. Patients need to know the expected duration, maintenance plan, price at higher doses, and options if a compound becomes unavailable.

Cost: compare the product and care, not only the banner price

Curex's advertised starting prices are lower than the historical list prices of branded injections and include medication and shipping. That can be valuable for someone without coverage. The correct comparison is not simply $149 versus a brand list price.

Compare the exact formulation, FDA status, pharmacy, dose escalation, clinician follow-up, lab costs, supplies, dietitian or behavioral support, and continuity plan. Also check current insurance coverage for approved Wegovy or Zepbound, manufacturer self-pay programs, and the new approved oral Wegovy option. An approved product may have a higher cash price but a stronger evidence and quality package; a compounded product may meet an individual need but should not be priced or marketed as if that distinction disappears.

Questions to ask before enrolling

1. What exact product, route, and dose would be prescribed for me?
2. Is the pharmacy 503A or 503B, and can I verify its license before payment?
3. Is compounded semaglutide made with semaglutide base or a salt?
4. Why is a compounded product clinically appropriate instead of an FDA-approved option?
5. What human evidence supports the exact oral dissolving formulation?
6. Which baseline information or labs are required in my case?
7. Who reviews my full medication list and weight-related conditions?
8. How often are follow-ups scheduled during escalation and maintenance?
9. Does the advertised price change with dose or formulation?
10. What is the plan if I have severe adverse effects, a shipment arrives warm, or the compound becomes unavailable?
11. What nutrition, resistance-training, and behavioral support is included?
12. What Curex-specific 6- and 12-month outcome and retention data are available?

Bottom line

Curex offers real telehealth access and advertises more support than the previous version of this page acknowledged. Its clearest limitations are product-specific: compounded injections are not the approved products studied in STEP 1 or SURMOUNT-1, and sublingual ODTs have a much thinner human evidence base than FDA-approved injectable or swallowed-tablet options.

The program may fit a patient with a documented need for a compound and a verified pharmacy. It should not be evaluated by price and branded-trial percentages alone. The better standard is transparent formulation, a patient-specific reason for compounding, claim-matched evidence, defined monitoring, coordinated chronic care, and outcomes from the actual program.